{
}
The global regenerative medicine market, valued at USD 31.90 billion in 2023, is projected to grow at a CAGR of 27.06%, reaching USD 349.93 billion by 2033. North America leads the market due to its advanced healthcare infrastructure and increasing demand for personalized medicine, while musculoskeletal conditions are expected to drive the fastest growth. However, high treatment costs and limited insurance coverage pose significant challenges to market expansion.
The global pediatric healthcare app market is projected to grow from $11.90 billion in 2023 to $58.72 billion by 2033, with a CAGR of 17.31%. North America is expected to dominate this market due to its advanced healthcare infrastructure, while Asia-Pacific is anticipated to experience the fastest growth. Key features of these apps include telemedicine, appointment scheduling, and personalized care, enhancing patient convenience and engagement.
The global red biotechnology market is projected to grow from $381.01 billion in 2023 to $699.31 billion by 2033, driven by rising chronic disease prevalence and increased healthcare funding. Key players like Pfizer and Amgen are advancing drug development, particularly in precision medicine, despite high trial failure rates. Recent mergers, such as Ipsen's acquisition of Albireo, highlight ongoing consolidation in the sector.
Johnson & Johnson (JNJ) has seen a year-to-date gain of 3.40%, significantly lagging behind the S&P 500's 22.48% rise. The company recently launched innovative fracture management technology and completed the acquisition of V-Wave Ltd. to enhance its heart disease treatment offerings. For Q3 2024, JNJ reported a 5.2% increase in sales to $22.47 billion, with analysts projecting a 4.3% revenue growth for the fiscal year, reflecting strong fundamentals and a "Strong Buy" rating.
Nations have established the "Cali Fund" to ensure companies sharing profits from genetic resources contribute to biodiversity preservation, targeting firms with significant revenues. However, the voluntary nature of contributions raises concerns about the impact on rapid vaccine development and access to genetic data, particularly amid ongoing pandemic negotiations. Critics warn that new regulations could hinder medical research, emphasizing the need for seamless access to digital sequence information for effective health responses.
Viking Therapeutics' oral obesity drug has shown promising results, with an average weight loss of about 8% after four weeks at the highest dose, raising expectations among analysts. Despite a 9% drop in shares following the announcement, experts noted the data's potential, comparing it favorably to competitors like Wegovy and Zepbound. Viking plans to initiate a Phase 2 study later this year while advancing its injectable version to Phase 3 trials.
The intratumor cancer therapies market, valued at $151.5 million in 2022, is projected to grow at a CAGR of 9.9% from 2023 to 2030, driven by advances in immunotherapy and personalized medicine. Monoclonal antibodies are leading the technology segment, while lung cancer remains the primary application area. North America is the dominant market, fueled by rising cancer prevalence and increased awareness of innovative treatment options.
Pfizer Inc., the leading global pharmaceutical company, generates net sales primarily from primary care products (52.3%), specialty care products (25.6%), and oncology products (19.9%). Geographically, sales are distributed with 42.3% in the United States, 21.9% in Europe, and 33.8% in other regions. UBS has reiterated its Neutral rating on the company.
UBS has maintained a 'Neutral' rating for Pfizer, setting a target price of $31 following an investor event. Analyst Trung Huynh noted the company's presentation on Ponsegromab's potential in treating cancer cachexia, with plans for quarterly updates on its development pipeline.
UBS has upgraded Pfizer to a 'Neutral' rating with a target price of $31, while Goldman Sachs and Jefferies have raised their targets to $33, recommending a 'Buy' rating. The pharmaceutical company has seen a sales increase due to a Covid-19 wave, prompting a positive outlook.
Pfizer Inc.
Companies
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
regenerative medicine market poised for rapid growth driven by innovation and demand
United States Dollar
Novartis AG
AbbVie Inc.
Hoffmann-La Roche AG
Pfizer Inc.
Johnson & Johnson
FRA
CHN
ESP
BRA
KOR
IND
ZAF
ITA
CAN
USA
JPN
MEX
GBR
DEU
ARE
AUS
Dr. Samuel Lynch
Pfizer
Lynch
Samuel Lynch
Johnson & Johnson
Show more
00:23 07.11.2024
asia-pacific leads rapid growth in patient-centric healthcare applications market
United States Dollar
Siemens Healthineers AG
Koninklijke Philips N.V.
Merck & Co., Inc.
Boston Scientific Society
Pfizer Inc.
FRA
CHN
ESP
BRA
KOR
IND
ZAF
ITA
CAN
USA
JPN
MEX
GBR
DEU
ARE
AUS
Show more
00:19 07.11.2024
global red biotechnology market poised for significant growth by 2033
United States Dollar
Novartis AG
Biogen Inc.
Amgen Inc.
Tesla, Inc.
Pfizer Inc.
CHN
FRA
ESP
BRA
KOR
IND
ZAF
ITA
SAU
ARG
CAN
USA
RUS
JPN
MEX
GBR
DEU
ARE
AUS
QAT
MedTech Acquisition Corporation
Ipsen
TriSalus Vie Sciences
Spheric Insights
Albireo
Show more
23:55 06.11.2024
pharmaceutical companies report strong earnings and new product approvals
12:26 06.11.2024
nations agree on biodiversity fund amid challenges for developing countries
United States Dollar
International Bank For Reconstruction And Development - World Bank Trust Funds
IFPMA
Moderna, Inc.
Pfizer Inc.
BioNTech
USA
FRA
NOR
GBR
AUT
David Reddy
Colman O’Criodain
Inger Andersen
Kirsten Schuijt
Show more
23:27 04.11.2024
viking therapeutics oral obesity drug shows promising early weight loss results
United States Dollar
Hoffmann-La Roche AG
Novo Nordisk A/S
Eli Lilly and Company
Pfizer Inc.
USA
Steven Seedhouse
Roger Song
Thomas Smith
Show more
17:53 04.11.2024
growth of intratumor cancer therapies market driven by innovative treatments and technologies
United States Dollar
Eli Lilly and Company
AbbVie Inc.
AstraZeneca PLC
Amgen Inc.
Novartis AG
Merck & Co., Inc.
Pfizer Inc.
F. Hoffmann-La Roche Ltd.
Bristol-Myers Squibb Company
Bayer AG
USA
Show more
06:23 04.11.2024
Pfizer maintains strong market position with diverse product sales distribution
20:58 01.11.2024
ubs maintains neutral rating on pfizer with target price of 31 dollars
20:58 01.11.2024
ubs and goldman sach upgrade pfizer amid positive sales outlook
United States Dollar
Pfizer Inc.
HSBC Holdings plc
Apple Inc.
McDonald's Corporation
USA
GBR
Show more
20:10 01.11.2024
Trending
Subcategory
Industry Trends
Corporate News
Startups & Entrepreneurship
Global Trade Developments
Government Economic Policies
Supply Chain Management
Retail and Consumer Goods
Stock Market Updates
Industry Mergers & Acquisitions
Venture Capital Investments
Energy Sector Developments
Finance Mergers & Acquisitions
Cryptocurrency & Blockchain Regulations
Global Financial Events
Central Bank Actions
Emerging Startups
Funding Rounds & Investments
Market Analysis and Predictions
Fintech Startups
Workplace Trends
Countries:
Companies:
Apple Inc.
NVIDIA Corporation
Google Inc.
Dell Technologies Inc.
Samsung Securities Co.,Ltd.
Learning Resources Inc.
MGA Entertainment Inc.
XPeng Inc.
Toyota Motor Corp
State Street Global Advisors Luxembourg SICAV - SSGA EMU ESG Screened Equity Fund
European Union Bonds
Taiwan Semiconductor Manufacturing Company Limited
Microsoft Corporation
Verizon Communications Inc.
SLB 4,6% 01JUN25
Equinor Ventures AS
Quanta Services, Inc.
Gold Circuit Electronics Ltd.
Unimicron Technology Corp.
Yatra Online, Inc.
Currencies:
United States Dollar
Chinese Yuan
Indian Rupee
Euro
Japanese Yen
United Arab Emirates Dirham
British Pound Sterling
Australian Dollar
New Taiwan Dollar
Vietnamese Đồng
New Zealand Dollar
South Korean Won
Egyptian Pound
Thai Baht
Saudi Riyal
Indonesian Rupiah
South African Rand
Malaysian Ringgit
Singapore Dollar
People: